- About Us
- Reproductive Health & Pregnancy Therapeutics
- Our Pipeline
- News & Events
Infertility affects about 10% of reproductive-aged couples, with approximately 1.6 million ART treatments (including in vitro fertilization and intracytoplasmic sperm injection) performed worldwide each year.
While the success of ART depends on multiple factors such as embryo quality and transfer procedure, success ultimately hinges on the receptivity of the uterus to accept implantation. Uterine contractions at the time of embryo transfer, as well as suboptimal thickness of the uterine wall and blood flow to the uterus, may impair the implantation of the embryo.
ObsEva is currently advancing nolasiban (OBE001), an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This increases the chance of successful implantation and live-birth rates among patients undergoing ART.
For a list of all ObsEva clinical trials in the area of ART, click here.